CITY THERAPEUTICS, INC.
CTYDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Therapeutic Anticoagulation
COVID-19
High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)
Multiple Myeloma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Therapeutic Anticoagulation | Phase 3 | COVID-19 | - | - |
High-Dose Melphalan HCL for Injection (Propylene Glycol-Free) | Phase 2 | Multiple Myeloma | - | - |
Frequently asked questions
What is in CITY THERAPEUTICS, INC.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in CITY THERAPEUTICS, INC.'s (CTY) pipeline across Phase 3, Phase 2. Its lead program is Therapeutic Anticoagulation (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CITY THERAPEUTICS, INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for CITY THERAPEUTICS, INC. (CTY) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CTY biotech catalysts?→
Add CTY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CITY THERAPEUTICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.